Biogen’s Tofidence, a biosimilar to Actemra, was granted FDA approval for treatment of Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis, according to a label posted to the site of the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
- Biogen Completes Acquisition of Reata Pharmaceuticals
- Biogen completes acquisition of Reata Pharmaceuticals
- Biogen, Eisai announce LEQEMBI Intravenous Infusion approved in Japan
- LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan